{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Katie", "organization": "", "rank": 1, "lastname": "THOMAS"}], "original": "By KATIE THOMAS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/09/16/business/08mylan1/08mylan1-thumbWide-v3.jpg", "legacy": {"wide": "images/2016/09/16/business/08mylan1/08mylan1-thumbWide-v3.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/09/16/business/08mylan1/08mylan1-articleLarge-v3.jpg", "legacy": {"xlarge": "images/2016/09/16/business/08mylan1/08mylan1-articleLarge-v3.jpg", "xlargewidth": "600", "xlargeheight": "456"}, "width": 600, "subtype": "xlarge", "height": 456}, {"type": "image", "url": "images/2016/09/16/business/08mylan1/16EPIPENLOBBY2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/16/business/08mylan1/16EPIPENLOBBY2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "Mylan to Pay $465 Million in EpiPen Overpricing Case", "main": "Mylan to Settle EpiPen Overpricing Case for $465 Million"}, "print_page": "1", "keywords": [{"value": "Mylan Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Medical Devices", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Justice Department", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Epinephrine (Drug)", "is_major": "Y", "rank": "4", "name": "subject"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Allergies", "is_major": "Y", "rank": "7", "name": "subject"}, {"value": "Generic Brands and Products", "is_major": "Y", "rank": "8", "name": "subject"}, {"value": "Medicaid", "is_major": "N", "rank": "9", "name": "subject"}], "snippet": "The government said Mylan had wrongly claimed EpiPen as a generic, leading Medicare and Medicaid to overpay for it. The company said the settlement included no admission of wrongdoing....", "source": "The New York Times", "lead_paragraph": "The government said Mylan had wrongly claimed EpiPen as a generic, leading Medicare and Medicaid to overpay for it. The company said the settlement included no admission of wrongdoing.", "word_count": "780", "pub_date": "2016-10-08T04:00:00+0000", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/10/08/business/epipen-mylan-justice-department-settlement.html", "_id": "57f8125495d0e021d798abfa"}